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Background: In the Netherlands, the first 5 years of follow-up after treatment for breast cancer are
carried out in hospital with yearly mammography. After this, for patients aged over 60 years who
have undergone mastectomy, there is a shift of care to the National Screening Programme (NSP) for
mammography every 2 years. After breast-conserving therapy follow-up is perfomed by the general
practitioner (GP), with mammography every second year and physical examination annually. The aim
of this study was to evaluate the clinical effects and costs of four different strategies for follow-up after
breast cancer treatment.
Methods: An extended and validated simulation model for breast cancer follow-up was used. The current
guidelines for follow-up (baseline strategy) and three less intensive follow-up strategies were evaluated.
The main outcome measure was the detection rate of small tumours (2 cm or smaller) and associated
costs for each strategy.
Results: Shortening the follow-up time in hospital by shifting care to the NSP or GP after 2 years instead
of 5 years of hospital follow-up, lowering the age of referral to the NSP or GP from 60 to 50 years,
and termination of annual physical examination by the GP after hospital follow-up did not decrease the
detection of small tumours. In addition, a substantial decrease in costs was observed with simplified
follow-up.
Conclusion: Decreasing hospital follow-up time, lowering the age of referral to the NSP or GP,
and termination of annual physical examinations would lead to a substantial reduction in costs while
maintaining the possibility of detecting small breast cancers.
Paper accepted 22 May 2012
Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.8850
Introduction
Breast cancer is the most common malignancy in women
in North America and Western Europe, accounting for
more than one in four diagnosed cancers1,2. Substantial
improvements in survival have been achieved and the 5-year
age-adjusted relative survival rate for patients with breast
cancer in European countries increased from 74 per cent
in 1988 to 83 per cent in 19993.
Routine follow-up for early detection of new primary
breast cancer is recommended after primary treatment and
constitutes the major part of healthcare for breast cancer
survivors4,5. There are several potential ways in which
hospitals can reduce this workload6,7. First, less frequent
follow-up including mammography and a shorter duration
of follow-up can be implemented8,9. Second, follow-up can
be provided by nurses or general practitioners (GPs). These
strategies have shown acceptable patient satisfaction and
comparable quality of life outcomes to those associated
with hospital follow-up10–12. Third, tailored approaches
can be developed, including individual risk assessment
of new primary breast cancers, age and co-morbidities,
and even psychological preferences13. A few randomized
controlled trials have evaluated these alternative follow-up
models, but none had enough statistical power to establish
the ideal frequency and safety of alternative follow-up
methods7.
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In the absence of adequate trial data, simulation mod-
elling can provide guidance on the risks, beneﬁts and
resources required for routine follow-up to detect early
primary breast cancers. The aim of the present study was
to evaluate the effectiveness and costs of different follow-up
strategies for women with a previous breast cancer. For this
simulation, a previously validated simulation-based deci-
sion model was extended14,15. The main outcome of the
study was the detection rate of early breast cancer and the
associated additional costs.
Methods
Population screened by the model
The input population screened by the model was based on
a database of women with a history of breast cancer that was
representative of the Dutch breast cancer population with
respect to age at diagnosis, tumour stage, nodal status and
treatment of the ﬁrst tumour. The women were diagnosed
with breast cancer between January 1989 and January 2003,
and treated in four hospitals in the North Netherlands.
Data were extracted from the patients’ medical records in
all hospitals using the registration and coding manual of
the Dutch Association of Comprehensive Cancer Centres.
Description of the simulation model
The structure of the model is shown in Fig. 1. The life of
each woman is simulated for each year from the moment
of detection of the ﬁrst breast cancer until death or until
a second breast cancer is detected. For each woman it is
simulated whether or not she dies. If she does not die, the
event ‘second breast cancer’ and the event ‘detection of this
second breast cancer’ are simulated. The probability of a
second breast cancer is calculated based on the current age
of the patient and the number of years since primary breast
cancer treatment. Tumours are selected randomly based
on this probability and are presumed to grow according to
the preclinical growth model. When a tumour is diagnosed
based on symptoms, it is considered as an interval tumour.
Otherwise it is checked whether a physical examination
and/or mammography is scheduled based on the selected
scenario and, if so, whether the woman will undergo
this examination based on her expected compliance. If
physical examination and/or mammography is performed,
a possible tumour can be detected based on the sensitivity
of the method. If a tumour is detected during that year,
the woman is diagnosed with a second breast cancer, the
screening is terminated and the simulation ends. If no new
cancer is detected, the woman’s age is increased, and the
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Fig. 1 Structure of the simulation model for follow-up after
curative treatment for breast cancer. The circles correspond to
the clinical state of the patient, the diamonds to decisions made
in the simulation programme, and the rectangles to the different
model components with parameters given in Tables 1 and 2.
Y, yes; N, no
Clinical parameters in the simulation model
The clinical parameters of the simulation model have been
described in previous publications14,15. For the purpose
of follow-up of women after primary breast cancer, the
input parameters of the model were adapted to the
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Table 1 Guideline recommendations for hospital follow-up
during the ﬁrst 5 years after primary treatment of breast cancer
(current strategy)
Physical breast examination Mammography
Year 1 Every 3 months Yearly
Year 2 Every 6 months Yearly
Years 3–5 Yearly Yearly
current Dutch screening scenario (Tables 1 and 2), and
in addition the model was extended and subsequently
validated. Compared with previous publications14,15, the
model was extended to include population death rates, the
risk of developing a second primary tumour, the sensitivity
of physical examination, the speciﬁcity of mammography
and physical examination, and patients’ compliance. In
addition, the input parameters of the model were changed
in accordance with the literature (Table S1, supporting
information)14–16.
The population death rate model used cumulative death
rates derived from Dutch data (http://www.rivm.nl). The
risk of developing a second primary breast cancer was
based on a publication on the incidence of breast cancer
among female cancer survivors diagnosed in the 1990s,
which was about 1 per cent per year17. The parameters
of the compliance model were estimated from a database
of 669 women with a history of breast cancer18. Finally,
the sensitivity and speciﬁcity model was extended with
an estimate for an age-dependent sensitivity of physical
examination, and was derived from data published by
Fryback and colleagues16. The speciﬁcity of physical
examination, 97·1 per cent, was added19. The sensitivity
of screening mammography depends on tumour size and
was based on the results of screening mammography in
women with a personal history of breast cancer20. The
speciﬁcity of mammography, 98·3 per cent, was added21.
Follow-up strategies studied
In theNetherlands, current guidelines recommendhospital
follow-up for 5 years with yearly mammography (Table 1).
After this follow-up, women aged over 60 years who
have undergone mastectomy are referred to the National
Screening Programme (NSP) for mammography every
second year. After breast-conserving therapy women are
referred to the GP for mammography every other year,
and annual physical examination. For the present study,
the current guidelines are indicated as the current strategy.
In the ﬁrst alternative strategy, follow-up time in hospital
was shortened by a shift of care from the hospital to
the NSP or GP after 2 years of follow-up. In the second
alternative strategy, hospital follow-up time was reduced
by a shift of care from the hospital to the NSP or GP
after 2 years of follow-up and by lowering the referral
age from 60 to 50 years. In the third alternative strategy,
hospital follow-up time was reduced by shifting care from
the hospital to the NSP or GP after 2 years of follow-
up, by lowering the referral age from 60 to 50 years,
and by terminating yearly physical examination in general
practice. The simulation model ran until every woman had
left the model owing to death or detection of a secondary
primary breast cancer.
Economic evaluation
A cost-effectiveness analysis was undertaken to evaluate
the balance between costs and effects of the various follow-
up strategies. The analysis considered the additional costs
associated with an increase of 1 per cent in the number
of early breast cancers detected (the percentage of second
primary tumours diagnosed with a size of 2 cm or less).
The cost of mammography was ¤92 in hospital22 and
¤53 in the NSP23. The cost per false-positive result for
pathological evaluation was ¤7524. The cost of a specialist
visit, including consultation and physical examination, was
Table 2 Differentiated follow-up proposed (at least) 5 years after primary treatment of breast cancer (current strategy)
After mastectomy After breast-conserving therapy
Age ≤ 60 years
Coordination Hospital Hospital




Coordination National screening programme General practitioner
Physical breast examination – Yearly
Mammography Every 2 years Every 2 years
Age > 75 years Follow-up can be ended Follow-up can be ended
MRI, magnetic resonance imaging.
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¤25. The total costs of treatment were estimated at ¤5857
for tumours of 2 cm or smaller, ¤6485 for tumours larger
than 2 cm up to 5 cm in size, and ¤7006 for tumours larger
5 cm at diagnosis25.
Statistical analysis
Values in parentheses presented in the text are 95 per cent
conﬁdence intervals. The model estimates were based on
1000 replications of the simulation performed for each
scenario.
Results
The input population screened by the model was based
on a database of 5073 women with a history of breast
cancer (Table 3). The model was validated by comparison
of simulation results with observed numbers in the database
regarding the following parameters: number of deaths,
number of tumours, and the number and percentage of
small, medium and large tumours. Only 384 (95 per cent
c.i. 347 to 421) deaths were simulated, whereas 518
deaths were recorded in the database (Fig. S1a, supporting
information). However, the database recorded all deaths,
including those after detection of a second primary breast
cancer, whereas in the simulation women left the model
when a second primary breast cancer was detected. A total
of 141 (114 to 167) tumours were found in the simulation,
which corresponded well with the 136 tumours in the
database (Fig. S1a, supporting information). The number
and percentage of small, medium and large tumours in the
simulation corresponded well with tumours in the database
(Fig. S1a,b, supporting information). The conﬁdence
Table 3 Characteristics of the population screened by the model
presented
No. of women (n = 5073)
Age at diagnosis (years)* 61·1(4·4)






















Values in parentheses are percentages unless indicated otherwise; values
are *mean(s.d.) and †median (range).
interval for the mean tumour size in the simulation,
1·4 to 2·1 cm, included the observed mean tumour size
of 1·5 cm in the database. Finally, the mean age of the
women diagnosed with a second tumour was 67·0 (41·5 to
92·5) years in the simulation, which was somewhat higher
than the mean age of 61·1 years for women included in the
database, but within the conﬁdence interval (32·9 to 89·3).









No. of second tumours 1043(9) 1047(10) 1042(9) 1053(9)
Programme sensitivity (%) 58·0(0·5) 57·9(0·6) 58·0(0·6) 58·4(0·6)
Sensitivity of clinical examination (%) 10·5(0·4) 10·3(0·3) 10·5(0·4) 9·7(0·3)
Sensitivity of mammography (%) 47·5(0·6) 47·6(0·6) 47·3(0·6) 48·7(0·6)
Total no. of clinical examinations (×1000) 41·9(0·2) 36·3(0·2) 36·3(0·1) 24·7(0·1)
Total no. of mammographies (×1000) 33·9(0·2) 32·1(0·2) 27·2(0·1) 26·6(0·1)
Mean invasive tumour size (cm) 1·80(0·05) 1·86(0·05) 1·95(0·04) 1·94(0·04)
Small tumours (%) 51·7(0·6) 51·5(0·6) 50·6(0·6) 50·6(0·6)
Medium tumours (%) 30·2(0·5) 30·3(0·5) 30·7(0·5) 29·6(0·5)
No. of false-positive findings (×1000) 1·82(0·02) 1·66(0·02) 1·51(0·02) 1·27(0·02)
No. of tumours in patients aged > 75 years 259(6) 261(6) 257(6) 266(6)
Screening cost (¤ million) 4·30(0·02) 3·98(0·02) 3·52(0·02) 3·16(0·01)
Cost per 1% increase in small tunours (¤ ×1000) 83·1(1·0) 77·3(0·9) 69·4(0·8) 62·1(0·8)
Total cost (¤ million) 11·3(0·1) 11·0(0·1) 10·5(0·1) 10·2(0·1)
Values are mean(s.d.) from 1000 simulations.
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The strategy for follow-up based on the current
guidelines as well as the three alternative strategies
showed no substantial differences in the number of second
tumours detected, in the programme sensitivity, and in
the sensitivity of physical examination or mammography
(Table 4). Applying the current strategy for follow-up, 51·7
(50·5 to 52·9) per cent of second tumours detected were
small and mean diameter was 1·80 (1·70 to 1·90) cm.
The ﬁrst alternative strategy produced a comparable rate
of small tumours (51·5 (50·3 to 52·7) per cent) and a
similar mean tumour size (1·86 (1·76 to 1·96) cm). With
the second strategy a comparable rate of small tumours
(50·6 (49·4 to 51·8) per cent) and mean tumour size (1·95
(1·87 to 2·03) cm) was found, and the third strategy yielded
similar results (50·6 (49·4 to 51·8) per cent and 1·94 (1·86
to 2·02) cm respectively).
There were appreciable differences in number of
clinical examinations, number of mammographies and
number of false-positive ﬁndings on mammography
between strategies. Consequently, there were substantial
differences in costs. Applying the current guidelines,
the total screening cost was estimated at ¤4·30 (4·26
to 4·34) million. The three alternative strategies were
associated with lower mean screening costs: ¤3·98 (3·94
to 4·02), 3·52 (3·48 to 3·56) and 3·16 (3·14 to 3·18) million
respectively. The third alternative strategy was the least
expensive, with an estimated cost of ¤62 100 (60 500 to
63 700) for increasing the detection of small tumours by
1 per cent.
Discussion
Shortening the follow-up time in hospital by shifting to
the NSP or GP after 2 years instead of 5 years, lowering
the age of referral from 60 to 50 years, and terminating
annual physical examination in general practice did not
decrease the percentage of small tumours detected during
follow-up. In addition, a substantial decrease in costs was
observed.
The results from three alternative strategies evaluated in
the present study suggest that women with breast cancer
can be referred to theNSP for mammography or to general
practice for follow-up by physical examination after an
initial 2-year hospital-based follow-up. These ﬁndings are
consistent with the results from a randomized clinical trial
in which follow-up in general practice of women with
breast cancer did not increase the time to diagnosis of
recurrence11,26.
In the second and third alternative strategies, the age
for referral from hospital-based follow-up to the NSP
or general practice was lowered from 60 to 50 years.
Mammography every second year instead of annually
would be recommended in these women. This would
lead to the number of mammographies for women aged
between 50 and 60 years being reduced from ten to ﬁve. In
the present simulation, this strategy was as safe as the one
proposed by the current guidelines. These results are in
agreement with studies demonstrating no adverse effects
associated with a 2-year screening interval among women
in their 50s or older27,28.
In the third alternative strategy, physical examination
was no longer performed after 2 years of follow-up. This
also turned out to be a safe strategy, with a comparable
mean tumour size and a similar percentage of small tumours
detected. These results are in agreement with a recent
meta-analysis indicating that few relapses are detected by
physical examination, and that patients diagnosed clinically
with a relapse may do less well29.
The model used in this study is an extension of a
validated model for the simulation of effects of breast
cancer screening14,15. There was no difference between
the expected results obtained using the current strategy
in the model and the observed results of the follow-up
database and published ﬁndings for theDutch breast cancer
population30,31.
The impact of shortening follow-up was studied in
the Dutch situation in which women are screened in the
NSP every other year. If the study had been performed
in the context of annual screening or screening every
third year, as in the UK, all strategies would have been
expected to show an increase or decrease respectively in
the percentage of small tumours detected. Only a small
decrease in the percentage of small tumours detected was
observed in the different strategies for screening every
second year. Therefore, if the screening frequency were
increased from every other year to annually, a difference
between the strategies in the detection of small tumours
would be unlikely. However, if the screening frequency
were decreased from every other year to every third year,
the detection of small tumours would decrease. This would
be especially true if the patients’ age for referral to the
NSP or GP were lowered from 60 to 50 years, as in the
second and third alternative strategies.
This study has some limitations. The percentage of small
tumours was used as an outcome instead of quality-adjusted
life years (QALYs). It is generally accepted that early
detection of second breast cancer will result in improved
survival32. A population-based study revealed that women
with stage II or higher breast cancer had worse survival,
whereas women with stage I breast cancer did not31. A
previous systematic review concluded that early detection
of isolated recurrences in patients without symptoms
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during follow-up was associated with substantially better
survival than late detection of recurrence32. It is unlikely
that the relative cost-effectiveness of the present four
strategies would change if QALYs were simulated as
the outcome. Another potential limitation of the present
study could be the use of the estimated preclinical tumour
growth derived from the general population instead of
a population of women with a history of breast cancer.
The tumour doubling times were based on data from Peer
and colleagues33 and these data are still considered to
be applicable. However, it is uncertain whether tumour
growth in women with a history of breast cancer differs
from that in the general population. As an example,
adjuvant treatment could inﬂuence tumour growth, which
may lower the detection rate in follow-up programmes.
The model incoporated Dutch cumulative death rates.
However, it is well known that women who survive breast
cancer are at an increased risk of death. Finally, the
local recurrence rate was not taken into account in the
present model used for simulation owing to the lack of
conclusive information on local recurrences. The model
would be improved by extending it to included the early
detection of locoregional recurrences. This would lead to a
decrease in sensitivity for tumour detection during follow-
up. However, as this would be the case for all follow-up
scenarios, it would not be expected to have a major impact
on the conclusions based on the present investigation.
The results of the present simulation-based study
indicate that a decrease in hospital follow-up time, lowering
the age of referral to the NSP or GP, and terminating
yearly physical examination after 2 years would lead to
a substantial reduction in costs while maintaining the
detection rate of early breast cancer.
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